Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

NCT00891930 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

BIOLOGICAL: Panitumumab
BIOLOGICAL: Ganitumab
DRUG: Irinotecan

Sponsor

NantBioScience, Inc.